Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Safety and Efficacy of Tegileridine in Painless Gastrointestinal Endoscopy

13. November 2026 aktualisiert von: Fangpeng Gao, Hainan Medical College

This single-center, randomized, double-blind, active-controlled clinical trial aims to evaluate the safety and efficacy of tegileridine, a biased μ-opioid receptor agonist, in patients undergoing gastrointestinal endoscopy under sedation, compared with sufentanil. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation were enrolled and randomly assigned in a 1:1 ratio to receive either tegileridine or sufentanil. The primary outcome is the incidence of respiratory depression. Secondary outcomes include the incidences of hypotension and postoperative nausea and vomiting, sedation success rate, supplemental propofol dose, procedure duration, recovery time, and patient satisfaction. This study will provide clinical evidence to support individualized and precision-based anesthesia strategies for gastrointestinal endoscopy.

Studienübersicht

Detaillierte Beschreibung

Background: Gastrointestinal endoscopy under sedation is a cornerstone of the diagnosis and treatment of digestive diseases, reducing patient discomfort and improving adherence. Conventional anesthesia with sufentanil and propofol is associated with significant adverse effects, including respiratory depression, gastrointestinal adverse reactions, postoperative nausea and vomiting (PONV), and hemodynamic fluctuations. Tegileridine mediates analgesia through preferential activation of G protein signaling at the μ-opioid receptor while reducing β-arrestin pathway activation, thereby lowering the risks of gastrointestinal adverse reactions and respiratory depression. To date, no clinical studies have investigated tegileridine for gastrointestinal endoscopy under sedation, and pharmacokinetic data and dose-adjustment guidelines for older adults remain unavailable.

Objectives: To systematically compare the safety and efficacy of tegileridine and sufentanil for gastrointestinal endoscopy under sedation, establish the suitability of tegileridine in this setting, and determine an appropriate dose for older patients, thereby supporting the development of individualized and precision-based anesthesia strategies.

Study Design: This is a single-center, randomized, double-blind, active-controlled trial. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation will be enrolled and randomly assigned in a 1:1 ratio to the tegileridine group or the sufentanil group. Participants, staff involved in administering sedation, and outcome assessors will be blinded to treatment allocation. Only the nurses responsible for preparing the study medications will be unblinded.

Study Population: Eligible patients will be aged 18-75 years, have a body mass index (BMI) of 18.0-28.0 kg/m², a Mallampati airway classification of I or II, and an American Society of Anesthesiologists (ASA) physical status classification of I or II, have no contraindications to routine gastroscopy, and provide written informed consent. Exclusion criteria include severe cardiopulmonary disease, hepatic or renal failure, a history of opioid allergy, chronic opioid dependence, hypokalemia, a history of QT interval prolongation, pregnancy, and breastfeeding. Patients whose gastroscopy lasts longer than 30 minutes or who experience adverse events that cannot be resolved with treatment will be withdrawn from the study.

Interventions: Patients in the tegileridine group will receive intravenous tegileridine at 0.01 mg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. Patients in the sufentanil group will receive intravenous sufentanil at 0.1 μg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental propofol at 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Outcome Measures: The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. Secondary outcomes include safety measures (hypotension, PONV, the need for airway interventions, and changes in vital signs at multiple time points), efficacy measures (sedation success rate, the number of supplemental propofol doses and total propofol dose, procedure duration, and recovery time), and patient satisfaction, assessed on a scale of 1-10.

Expected Results: Compared with the sufentanil group, the tegileridine group is expected to have a lower incidence of respiratory depression, a lower risk of PONV, and more stable vital signs while achieving adequate analgesia for gastrointestinal endoscopy under sedation. Tegileridine may therefore offer a safer anesthesia option for older patients and patients with obesity.

Studientyp

Interventionell

Einschreibung (Geschätzt)

338

Phase

  • Phase 4

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Fang Peng Gao, MS
  • Telefonnummer: 17760577442
  • E-Mail: gao1664@163.com

Studienorte

    • Hainan
      • Haikou, Hainan, China, 570311
        • Rekrutierung
        • The Second Affiliated Hospital of Hainan Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Patients aged 18-75 years scheduled for gastrointestinal endoscopy under sedation.
  2. Body mass index (BMI) of 18.0-28.0 kg/m².
  3. Mallampati airway classification of I or II.
  4. American Society of Anesthesiologists (ASA) physical status classification of I or II.
  5. No contraindications to routine gastroscopy.
  6. Written informed consent signed by the patient and their family member.

Exclusion Criteria:

  1. Severe cardiopulmonary disease.
  2. Hepatic or renal failure.
  3. History of opioid allergy.
  4. Chronic opioid dependence.
  5. Hypokalemia or a history of QT interval prolongation.
  6. Pregnancy or breastfeeding.

Withdrawal Criteria:

  1. Gastroscopy duration exceeding 30 minutes.
  2. Adverse events that cannot be resolved with treatment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Tegileridine Group

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Aktiver Komparator: Sufentanil Group

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg.

Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Respiratory Depression
Zeitfenster: Periprocedural, up to 2 hours

The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%.

Periprocedural, up to 2 hours

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of Hypotension
Zeitfenster: Periprocedural, up to2 hours

Hypotension is defined as a decrease in systolic blood pressure (SBP) of more than 20% from baseline. The incidence of hypotension will be assessed during the periprocedural observation period and reported as the percentage of participants experiencing at least one episode of hypotension.

Periprocedural, up to2 hours
Incidence of Postoperative Nausea and Vomiting (PONV)
Zeitfenster: Periprocedural, up to 24 hours after the endoscopic procedure

The incidence of postoperative nausea and vomiting (PONV) will be assessed within 24 hours after completion of the endoscopic procedure. PONV is defined as the occurrence of at least one episode of nausea, vomiting, or both during the observation period. The outcome will be reported as the percentage of participants experiencing PONV.

Periprocedural, up to 24 hours after the endoscopic procedure
Heart Rate
Zeitfenster: Periprocedural, up to 2hours

Heart rate (beats/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2hours
Mean Arterial Pressure
Zeitfenster: Periprocedural, up to 2 hours

Mean arterial pressure (MAP, mmHg) will be recorded at the following six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Respiratory Rate
Zeitfenster: Periprocedural, up to 2 hours

Respiratory rate (breaths/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Peripheral Oxygen Saturation
Zeitfenster: Periprocedural, up to 2 hours

Peripheral oxygen saturation (SpO₂, %) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room.

Periprocedural, up to 2 hours
Percentage of Participants With Successful Sedation Based on Body Movement at Endoscope Insertion and Rescue Sedative Use
Zeitfenster: Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.

Percentage of participants who meet both criteria for successful sedation: no body movement at endoscope insertion and no use of any rescue sedative other than the study drug during the endoscopic procedure.

Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
Number of Supplemental Propofol Doses and Total Propofol Dose
Zeitfenster: Periprocedural, up to 2 hours

The number of supplemental propofol doses administered during the endoscopic procedure will be recorded for each participant. The total propofol dose (mg), including the initial dose and all supplemental doses, will also be calculated. Both outcomes will be assessed at the completion of the endoscopic procedure.

Periprocedural, up to 2 hours
Procedure Duration
Zeitfenster: During the endoscopic procedure

Procedure duration is defined as the time interval from endoscope insertion to endoscope withdrawal, measured in minutes.

During the endoscopic procedure
Recovery Time
Zeitfenster: Periprocedural,up to 2 hours

Recovery time is defined as the time interval from endoscope withdrawal to the time when the participant first meets the predefined discharge criteria for the post-anesthesia care unit (PACU), measured in minutes.

Periprocedural,up to 2 hours
Patient Satisfaction
Zeitfenster: Post-procedure assessment.
Post-procedure assessment.
Sedation Success Rate
Zeitfenster: At the end of the procedure.
At the end of the procedure.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

6. Juni 2026

Primärer Abschluss (Geschätzt)

10. November 2026

Studienabschluss (Geschätzt)

30. November 2026

Studienanmeldedaten

Zuerst eingereicht

28. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

13. November 2026

Zuerst gepostet (Tatsächlich)

18. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

13. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren